Skip to main content
NYRADA INC. logo

NYRADA INC. — Investor Relations & Filings

Ticker · NYR ISIN · AU0000070195 ASX Professional, scientific and technical activities
Open in API
Filings indexed 472 across all filing types
Latest filing 2025-09-15 Regulatory Filings
Country AU Australia
Listing ASX NYR

About NYRADA INC.

https://www.nyrada.com

Nyrada Inc. specializes in the development of novel small molecule therapeutic agents designed to address unmet needs in cardiovascular health and neuroprotection. The company’s lead programs include a cholesterol-lowering treatment and a neuroprotective treatment for brain injury. The cardiovascular program focuses on an oral PCSK9 inhibitor aimed at managing low-density lipoprotein (LDL) cholesterol levels as an alternative to injectable biologics. The neuroprotection program involves the development of NYR-BI03, a first-in-class small molecule designed to mitigate secondary brain damage following a stroke or traumatic brain injury by targeting canonical transient receptor potential (TRPC) ion channels. These efforts aim to provide effective, accessible pharmacological interventions for both chronic metabolic conditions and acute neurological trauma.

Recent filings

Filing Released Lang Actions
Xolatryp Protects Cells through Mitochondrial Stabilisation 4 pages 354.3KB
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from Nyrada Inc. about further analysis results of a preclinical study on their drug candidate Xolatryp, including scientific data, study background, and future clinical trial plans. It contains no financial statements, no regulatory certifications, no voting results, no management changes, no earnings highlights, and no direct financial performance data. It is a scientific and clinical update rather than a financial or regulatory filing. The document is longer than 5,000 characters and provides substantive information about the drug's mechanism and study results, but it is not a formal financial report or regulatory filing. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about clinical study results and company progress that does not fit into other specific categories like earnings release or capital update.
2025-09-15 English
Change in substantial holding - M Azzi 2 pages 257.2KB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Notice of Change of Interests of Substantial Securityholder' and details changes in the voting power and holdings of a substantial shareholder, Mr. Mark Azzi, in Nyrada Inc. It includes specific numbers of shares/CDIs held before and after the change, along with voting power percentages. The document is a formal announcement of a change in significant share ownership levels, which aligns with the definition of 'Major Shareholding Notification' (MRQ). There is no indication that this is a full financial report, audit, or other types of filings. The document length is 4046 characters, which is consistent with a notification rather than a full report. Therefore, the correct classification is MRQ with high confidence.
2025-09-10 English
Application for quotation of securities - NYR 6 pages 18.3KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 2A - Application for quotation of securities' and is an announcement from NYRADA INC. regarding the application for quotation of securities on the ASX. It details the securities issued as a result of options being exercised or convertible securities being converted, including numbers, issue dates, and other issuance details. The document is a formal application for listing new securities rather than a report on financial performance or management. It fits the category of Share Issue/Capital Change announcements, which cover new share issues or capital changes. The document length is about 6000 characters, and it is not a report publication announcement or a certification. Therefore, the appropriate classification is SHA (Share Issue/Capital Change).
2025-09-08 English
Cleansing Statement 2 pages 235.9KB
Capital/Financing Update Classification · 95% confidence The document is titled 'Cleansing Statement' and announces the issue of 90,000 CHESS Depositary Interests (CDIs) related to options exercised. It references compliance with sections of the Corporations Act 2001 (Cth) and provides legal assurances about disclosure obligations. The document is short (3278 characters) and primarily serves as a regulatory notice about a share issue without detailed financial data or analysis. It does not contain financial statements or substantive financial performance information. This fits the profile of a capital or financing update, specifically about share issuance and compliance with disclosure laws. Therefore, the document is best classified as a Capital/Financing Update (CAP).
2025-09-08 English
Securities Trading Policy 8 pages 391.8KB
Governance Information Classification · 95% confidence The document is titled 'Securities Trading Policy' and details the company's internal policy on insider trading, blackout periods, and trading restrictions for directors and senior executives. It does not contain financial statements, earnings data, or regulatory filings such as audit reports or annual reports. It is a governance-related document outlining rules and compliance for securities trading within the company. There is no indication that this is an announcement of a report or a certification. Therefore, the document best fits the category of Governance Information (CGR), which covers reports detailing the company's internal rules and governance practices.
2025-08-21 English
Preliminary Final Report 2 pages 446.6KB
Annual Report Classification · 95% confidence The document is titled 'Nyrada Inc. Appendix 4E Preliminary final report' and covers the financial year ended 30 June 2025. It includes detailed financial results such as revenues, losses, net tangible assets, and audit information with an unmodified opinion. The document also references compliance with Australian Accounting Standards and IFRS. The length is 2785 characters, which is relatively short, but the content includes substantive financial data and audit details, indicating it is a financial report rather than just an announcement. The mention of 'Appendix 4E' aligns with Australian regulatory filings for preliminary final reports, which are typically annual reports or closely related to them. The document states that the Annual Report for the year ended 30 June 2025 is attached, but this document itself contains detailed financial results and audit information, not just a notice of publication. Therefore, it should be classified as an Annual Report (10-K equivalent).
2025-08-21 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.